# Olaparib Monotherapy and Olaparib + Pembrolizumab Combination Therapy for Ovarian Cancer

> **NCT04417192** · PHASE2 · COMPLETED · sponsor: **National Cancer Center Hospital East** · enrollment: 30 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Olaparib
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04417192
- **Lead sponsor:** National Cancer Center Hospital East
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-01
- **Primary completion:** 2023-06-30
- **Final completion:** 2023-06-30
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2023-07-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04417192

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04417192, "Olaparib Monotherapy and Olaparib + Pembrolizumab Combination Therapy for Ovarian Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04417192. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*